Conatus Pharmaceuticals Could Become A Buyout Target
By: Bret Jensen
Conatus Pharmaceuticals (NASDAQ:CNAT), a company whose main drug candidate, Emricasan, is aimed at treating a variety of liver diseases and seems a perfect fit for Gilead. Emricasan is a first-in-class, orally-active protease inhibitor designed to reduce inflammation in the liver by interfering with certain biochemical pathways. I think Gilead or any other potential acquirer will wait for positive results for Emricasan. However, given the company's "shots on goal", low market capitalization and cash on the balance sheet, I like its risk/reward profile.
Drones will be used in government, space, aviation, will be huge.
Apple shares slump as new products fail to surprise
Aaron Pressman Yahoo Finance By Aaron Pressman1 hour ago
Apple does phones an iPads ,NFLX has the streaming market. This will only make NFLX stronger as usual.
Not uncommon SEC form gives buyout away- buy opp
SEC Form 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
1. Name and Address of Reporting Person
ANIDO ARMANDO X Director
X Officer (give title below)
ZYNERBA PHARMACEUTICALS, INC.1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/10/2015 C 26,595 A (1) 26,595 I See footnote (3)
Common Stock 08/10/2015 C 13,297 A (1) 13,297 I
This ain't brain surgery, it's the better drug and the better drug takes the market.
will get all the market share